



IJPPR

INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals

ISSN 2349-7203




Human Journals

Case report

November 2016 Vol.:7, Issue:4


© All rights are reserved by Dr. C Sugunakar Raju et al.

A Case Report on Paracetamol Induced Generalized Fixed Drug Eruptions



IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals

ISSN 2349-7203



Dr. Suresh Sake¹, Dr. C Sugunakar Raju*¹, Dr. Parveen¹, P. Mohammed Shafi², K. Sarath Chandra Reddy³, Lakkireddy Kavya⁴

¹*Consultant Dermatologist in Internal Medicine, Rural Development Trust Hospital (RDT), Bathalapalli, Anatapur, India – 515661*

¹*Assistant professor, Department of Pharmacy Practice (Pharm D), P Rami Reddy Memorial College of Pharmacy, Kadapa, India – 516003*


^{1,2,3,4}*Department of Pharmacy Practice (Pharm D), P Rami Reddy Memorial College of Pharmacy, Kadapa, India – 516003.*

Submission: 10 November 2016
Accepted: 15 November 2016
Published: 25 November 2016

Keywords: Skin Eruptions, Paracetamol, FDE, ADR

ABSTRACT

Generalized Fixed Drug Eruptions (FDE) is a type of drug-induced skin reaction pattern that characteristically recurs at the face, chest, same skin or mucosal site. Paracetamol is one of the common drugs prescribed as analgesic–antipyretic agent in all age group of patients. FDE is a well-reported, but uncommon side-effect of paracetamol, usually the classic, pigmenting type most commonly found in children and adolescents. We present a case of 10 years old male patient who developed Generalized FDE over the back, abdominal region, face and chest region and total body following paracetamol use.



HUMAN JOURNALS

www.ijppr.humanjournals.com

INTRODUCTION

Paracetamol also known as acetaminophen is one of the most popular and most commonly used analgesic and antipyretic drugs around the world and available without a prescription, both in mono- and multi-component preparations. It is a drug of choice in patients in whom application of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) are contraindicated, e.g., in the case of gastric ulcers, hypersensitivity to aspirin, impairments in blood coagulation, in pregnant women, nursing mothers and children with fever accompanying a disease¹. The central analgesic action of paracetamol is like aspirin, i.e. it raises pain threshold but has weak peripheral anti-inflammatory component², Paracetamol may act by inhibiting COX-3 in CNS, which is involved in pain perception and fever but not in inflammation. Another explanation for its lack of anti-inflammatory action is that it poorly inhibits COX-1 in the presence of superoxides which are generated at inflammatory sites by leukocytes³. Paracetamol is generally well tolerated at recommended dose. Prolonged daily use can lead to serious side effects like kidney or liver damage^{4,5}, stomach bleeding⁶, Hypersensitivity⁷, (anaphylaxis^{8,9} and fixed drug eruptions¹⁰) and Dermatological side effect like erythematous skin rashes associated with paracetamol have been reported but are rare. We have reported a case of paracetamol fixed drug eruptions.

CASE REPORT

A 10 years old male patient was brought with a history of erythema rash that started on back and gradually became generalized all over the body, soles and mucosal surfaces over a period of since 1 year recurrently. Rashes were well-circumscribed, 5-7 cm in size with a burning sensation without itching and blebs or pustules formation. These rashes were associated with intermittent moderate grade fever without chills and rigors. There was no history of similar complaints in the past. Hence, the provisional diagnosis of generalized erythematous rash of allergic origin was made. After admission, patient has given tablet paracetamol 500 mg three times a day, tablet prednisolone 10 mg twice a day and tablet chlorpheniramine maleate 25 mg twice a day. This oral treatment was also supplemented with intravenous fluids. The same day, late in the evening patient accidentally noticed erythematous, macular, multiple lesions with size varying between 1 and 2 mm over the face and chest region, there was no itching, scaling or burning. Immediately, withdrawal of paracetamol was initiated suspecting it to be the causative agent. Thereafter, erythema associated with the lesions over the face started subsiding over next 2 days. On the 3rd

day after withdrawal of tablet paracetamol, erythema lesions over the over the total body completely evolved into hyperpigmented lesions in the phase of recovery. Paracetamol induced Generalized FDE is shown in **FIGURE 01**. The probability of Generalized FDE due to paracetamol cannot be ruled out after applying Naranjo's scale of causality assessment of adverse drug reactions with a score of 4. Laboratory investigations such as hemoglobin, complete blood count, and blood sugar level were found to be within normal limits. Rest of the treatment was continued and the initial symptoms improved over next 5 days. WHO ADR assessing scale karch and lasagna results were shown in **TABLE 01**. We also assessed the severity, predictability and preventability as a part of management through modified hart wig and Siegel severity scale, schomok and Thornton preventability scale.



Figure 1: Paracetamol induced Generalized FDE.

ADR Management:

Generally, management of ADR includes withdrawal/suspension, dose reduction of suspected drug and administration of supportive therapy. Here in this case report, the suspected drug paracetamol was discontinued.

ADR analysis:

Table 01: Causality assessment of suspected ADRs.

Suspected and Reaction	Naranjos Scale	WHO-Probability Scale	Karch and Lasagnas Scale
Paracetamol induced fixed drug eruptions	Possible	Probable	Probable

SEVERITY: -Moderate level 4

PREDICTABILITY: -unpredictable

PREVENTABILITY: -Probably preventable

DISCUSSION

FDE is a cutaneous ADR which is commonly seen in children and adolescents. It is characterized by recurrent eruptions when the offending drug is re-administered. The hallmark of FDE is the recurrence in the same site on repeated administration of the offending drug¹¹. In our case, the patient has erythematous rash that started on back and gradually became generalized all over the body sparing palms, soles surfaces over a period of 3 days had over the face same area, Rashes were well-circumscribed, 5-7 cm in size with a burning sensation without itching and blebs or pustules formation i.e., cutaneous surface. Paracetamol induced FDE is reported in the literature in <1.5% of all cases of FDE¹². This case is unusual because the affected patient was of the elder age group, whereas FDE affects children and adolescents. This could be attributed to the hyper-immune reaction which sensitized the individual to paracetamol. Besides, in this case, both cutaneous and some hyperpigmented manifestations. This case reflects a broad spectrum of events in FDE. Erythematous appearance is indicative of active phase of FDE¹³, whereas the violet macular rash over the trunk and forearm imply recovery phase, which is characterized by hyperpigmented areas¹⁴, the assessment of ADR is done by means of Naranjo's ADR scale. A score of >9 is indicative of definite ADR. A score of 1-4 is indicative of possible ADR¹⁵. Our patient had a score of 4, thus indicative of FDE. The present case shows a temporal relation between the drug paracetamol and the presence of FDE. A patch test would have been useful in

this case, but the patch test must be done on cases that are not on any immunosuppressants. In our case, patient was on tablets chlorpheniramine maleate, prednisolone from 1st day. Hence, a patch test would have yielded better results.

CONCLUSION

Paracetamol is widely prescribed by physician as well as also a popular OTC drug. Physician must suspect if such reaction occurs during therapy involving paracetamol and should carefully evaluate drug-associated reaction. It is important that skin reactions are identified and documented in the patient record and patient should be explained properly not to use that drug so that their recurrence can be avoided in future.

REFERENCES

1. Leung L. From ladder to platform: a new concept for pain management. *J Prim Health Care*. 2012; 4:254.
2. Tripathi KD. Nonsteroidal anti-inflammatory drugs and antipyretic-analgesic. In: Tripathi KD, eds. *Essentials of Medical Pharmacology*. 6th ed. New Delhi, India: Jaypee Brothers Medical Publishers (P) Ltd.; 2008: 198.
3. Sharma HL, Sharma KK. Non-steroidal anti-inflammatory agents, antirheumatic drugs and antigout drugs. In: Sharma HL, Sharma KK, eds. *Principles of Pharmacology*. 1st ed. India: Paras Publications; 2007: 374.
4. Sarg Michael, Ann D. Gross, Roberta Altman. The cancer dictionary. In: Sarg Michael, Ann D. Gross, Roberta Altman, eds. *A Book*. USA: Infobase Publishing; 2007.
5. BBC News. Painkillers cause kidney damage, November 23, 2003. Available at: <http://news.bbc.co.uk/2/hi/health/3271191.stm>. Accessed 27 March 2010.
6. Garcia Rodriguez LA, Hernandez-Diaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen and combinations of these agents. *Arthritis Res Ther*. 2000 Dec; 3(2):98-101.
7. Kalyoncu AF. Acetaminophen hypersensitivity and other analgesics. *Ann Allergy*. 1994; 72:285.
8. Leung R, Plomley R, Czarny D. Paracetamol anaphylaxis. *Clin Exp Allergy*. 1992; 22:831-3.
9. Van Diem L, Grilliat JP. Anaphylactic shock induced by paracetamol. *Eur J Clin Pharmacol*. 1990; 38:389-90.
10. Kawada A, Hiruma M, Noguchi H, Ishibashi A. Fixed drug eruption induced by acetaminophen in a 12-year-old girl. *Int J Dermatol*. 1996; 35:148-9.
11. Balakrishna S, Vijayakumar S, Kumar PS, Upadhyaya J. Stevens-Johnson syndrome (SJS) and fixed drug eruption (FDE): A case report. *Int J Pharm Sci Lett* 2013; 3:257-9.
12. Hire RC, Sontakke S, Dakhale GN, Kamble A, Kale AS. Paracetamol induced fixed drug eruption: A case report. *Int J Basic Clin Pharmacol* 2014; 3:399-400.
13. Sánchez-Borges M. Hypersensitivity reactions to non-steroidal anti-inflammatory drugs: An update. *Pharmaceuticals* 2010; 3:10-8.
14. Murray VK, DeFeo CP. Intraoral fixed drug eruption following tetracycline administration. *J Periodontal* 1982; 53:267-8.
15. Zaki SA. Adverse drug reaction and causality assessment scales. *Lung India* 2011; 28:152-3.